The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Risk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial Infarction

Jerry H. Gurwitz, MD; Joel M. Gore, MD; Robert J. Goldberg, PhD; Hal V. Barron, MD; Timothy Breen, PhD; Amy Chen Rundle, MS; Michael A. Sloan, MD; William French, MD; and William J. Rogers, MD
[+] Article, Author, and Disclosure Information

For the Participants in the National Registry of Myocardial Infarction 2 Acknowledgment: The authors thank Bessie Petropoulos for assistance with manuscript preparation. Grant Support: The National Registry of Myocardial Infarction is supported by Genentech, Inc., South San Francisco, California. Requests for Reprints: Jerry H. Gurwitz, MD, The Meyers Primary Care Institute, University of Massachusetts Medical School and the Fallon Healthcare System, 100 Central Street, Worcester, MA 01608. Current Author Addresses: Dr. Gurwitz: The Meyers Primary Care Institute, University of Massachusetts Medical School and the Fallon Healthcare System, 100 Central Street, Worcester, MA 01608.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1998;129(8):597-604. doi:10.7326/0003-4819-129-8-199810150-00002
Text Size: A A A

Background: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarction has been unequivocally shown. However, thrombolysis is related to bleeding complications, including intracranial hemorrhage.

Objective: To determine the frequency of and risk factors for intracranial hemorrhage after recombinant tissue-type plasminogen activator (tPA) given for acute myocardial infarction in patients receiving usual care.

Design: Large national registry of patients who have had acute myocardial infarction.

Setting: 1484 U.S. hospitals.

Patients: 71 073 patients who had had acute myocardial infarction from 1 June 1994 to 30 September 1996, received tPA as the initial reperfusion strategy, and did not receive a second dose of any thrombolytic agent.

Measurement: Intracranial hemorrhage confirmed by computed tomography or magnetic resonance imaging.

Results: 673 patients (0.95%) were reported to have had intracranial hemorrhage during hospitalization for acute myocardial infarction; 625 patients (0.88%) had the event confirmed by computed tomography or magnetic resonance imaging. Of the 625 patients with confirmed intracranial hemorrhage, 331 (53%) died during hospitalization. An additional 158 patients (25.3%) who survived to hospital discharge had residual neurologic deficit. In multivariable models for the main effects of candidate risk factors, older age, female sex, black ethnicity, systolic blood pressure of 140 mm Hg or more, diastolic blood pressure of 100 mm Hg or more, history of stroke, tPA dose more than 1.5 mg/kg, and lower body weight were significantly associated with intracranial hemorrhage.

Conclusions: Intracranial hemorrhage is a rare but serious complication of tPA in patients with acute myocardial infarction. Appropriate drug dosing may reduce the risk for this complication. Other therapies, such as primary coronary angioplasty, may be preferable in patients with acute myocardial infarction who have a history of stroke.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.